Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Active Comparator-Controlled, Parallel-Group, Single-Blind, Multicenter, Phase III Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex) in the Treatment of Anemia Associated With Chronic Renal Failure in Pre-dialysis Patients

NCT03521713 is registered in ClinicalTrials.gov with Dong-A ST Co., Ltd. as lead sponsor.

NCT NCT03521713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03521713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Active Comparator-Controlled, Parallel-Group, Single-Blind, Multicenter, Phase III Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex) in the Treatment of Anemia Associated With Chronic Renal Failure in Pre-dialysis Patients
Lead sponsor
Dong-A ST Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
March 1, 2016
Completion date
March 31, 2021
Enrollment
214 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia of chronic kidney disease